A carregar...
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
The immunotherapy agent pembrolizumab has been approved for gastric cancer (GC) patients with recurrent or advanced disease who are PD-L1 positive. Mutations in the primary lesion may drive the expression of immune targets thereby priming the tumor to therapeutic sensitivity. In this study, we aimed...
Na minha lista:
| Publicado no: | Front Pharmacol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Frontiers Media S.A.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6331584/ https://ncbi.nlm.nih.gov/pubmed/30670970 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.01522 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|